Departments of Pediatric Oncology.
Department of Hematology/Oncology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
J Pediatr Hematol Oncol. 2023 Apr 1;45(3):e419-e422. doi: 10.1097/MPH.0000000000002555. Epub 2022 Sep 22.
TCF3-HLF-positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has an extremely poor prognosis. A 2-year-old boy with TCF3-HLF-positive BCP-ALL had an isolated extramedullary relapse in multiple bones after allogeneic hematopoietic stem cells transplantation (HSCT) from a human leukocyte antigen-matched unrelated donor. In this study, he received a T-cell-replete haploidentical HSCT (TCR-haplo-HSCT) from his father when in nonremission state, which resulted in a sustained complete remission for over 3 years. Immune therapies for patients with an extramedullary relapse of TCF3-HLF-positive BCP-ALL have been attempted; however, long-term efficacies of these therapies remain unknown. Our TCR-haplo-HSCT may be an effective therapeutic option for such patients.
TCF3-HLF 阳性 B 细胞前体急性淋巴细胞白血病(BCP-ALL)的预后极差。一名 2 岁男孩在接受 HLA 匹配的无关供体异基因造血干细胞移植(HSCT)后发生孤立性髓外复发,患有 TCF3-HLF 阳性 BCP-ALL。在这项研究中,当处于非缓解状态时,他从父亲那里接受了 T 细胞丰富的单倍体 HSCT(TCR-haplo-HSCT),这导致他持续完全缓解超过 3 年。已经尝试对 TCF3-HLF 阳性 BCP-ALL 髓外复发患者进行免疫治疗;然而,这些治疗的长期疗效尚不清楚。我们的 TCR-haplo-HSCT 可能是此类患者的有效治疗选择。